The course of disease in patients suffering from chronic lymphocytic leukemia (CLL) is determined by a profound dysregulation of the immune system. The resulting immune suppression is the main cause of death in those patients. In the present study we addressed the question of whether leukemic B cells ( 
Introduction
Chronic lymphocytic leukemia is predominantly a B cell neoplasia which is characterized by the accumulation of small, long-lived, slowly dividing monoclonal CD5 + B cells. The clinical course of the disease is predominantly determined by a profound dysregulation of the immune system, rather than by infiltration and destruction of organs, 1 resulting in various infections 2 and signs of autoimmunity. 3 It has been shown that almost 60% of deaths are caused by bacterial or viral infections. 4 Mycobacterial or fungal infections are less frequent. 1 Autoimmune-associated phenomena are mainly directed against hematopoietic cells 5 and are manifest as autoimmune hemolytic anemia (occurring in 10-25% of patients 1 ) or immune thrombocytopenia (observed in 2% of cases). Remarkably, the autoantibodies are apparently made by 'normal' B lymphocytes. 6 Hypogammaglobulinemia, occurring in up to 60% of B-CLL cases, 7 is probably also a result of dysfunction of nonclonal B cells. Thus, the intimate interaction of leukemic B cells with cells of the normal immune system is thought to play an important role in the pathogenesis of the disease.
It has been documented in a number of systems that B-CLL cells are able to interact with helper T cells. 8, 9 B-CLL lympho-cytes express cell surface molecules and receptors according to their postulated normal counterparts, CD5 + follicular mantle cell B lymphocytes. 10 Therefore, they can be stimulated by lymphokines or contact-dependent T helper cell signals similar to normal B lymphocytes. [11] [12] [13] [14] T cells, isolated from CLL patients, exhibit normal T-helper cell function in respect of cytokine secretion and proliferative responses after polyclonal activation. 15 The predominance of B cells as accessory cells, however, apparently alters the immune function of T helper cells in vitro, resulting in an enhanced secretion of interleukin-2, whereas interferon-␥ was only slightly induced and IL-4 was not expressed. 15 The communication between T helper cells and B cells relies upon the time course of the delivery of multiple signals. The activation of helper T cells depends upon the MHCrestricted activation of the T cell receptor by the antigen/MHC complex and is regulated by a number of co-stimulatory molecules such as CD80 and CD86. 16 The most important receptor system that mediates cell contact-dependent T cell help is the CD40/CD40-ligand receptor system. 17 The CD40 molecule has been shown to be present on normal and neoplastic B lymphocytes 18 and is able to transmit signals for the activation and differentiation of B cells. 13, 19 The ligand for CD40 is expressed on activated T lymphocytes and the interaction of CD40 with its ligand appears to be crucial for normal B lymphocyte differentiation and development. 20 Taken together there is circumstantial evidence that B-CLL can interact with helper T cells not only in vitro but also in vivo. However, the events leading to the observed immune dysregulation in these patients are not completely understood. Here we describe that in certain, but not all cases of B-CLL, the malignant B cells can competitively inhibit T cell contactdependent activation of normal B cells in vitro. Furthermore, we provide evidence that B-CLL cells can suppress the CD40 ligand mediated helper signal in particular. This could be an important mechanism by which B-CLL cells perturb normal helper T cell/B cell interactions in patients suffering from B-CLL.
Materials and methods

T cell clones
The CD4
+ T cell clones were obtained by random T cell cloning of peripheral blood lymphocytes (PBL) from healthy donors. PBL at a calculated number of 0.5 PBL/well were cocultivated with 2 × 10 4 irradiated feeder cells (PBL mixed with EBV-blasts, 3:1) in 96-well round bottom plates (Costar, Cambridge, MA, USA). The clones were expanded in RPMI 1640 (Gibco, Karlsruhe, Germany) supplemented with 10% Lymphocult (Biotest, Dreieich, Germany), 10% human AB-serum (BRK-Blutspendedienst, Wü rzburg, Germany) and 100 U/ml IL-2 (IL-2 was kindly provided by Prof Dr W Sebald, Wü rzburg).
CD40 ligand expressing L cells
CD40 ligand transfectants were prepared as described. 21 These cells were trypsinized, washed and plated out in 96-well plates at 3 × 10 3 cells/well, in 24-well plates at 1.5 × 10 4 /well. Cells transfected only with the pSV2neo plasmid were used as negative controls.
B cell preparations
B-CLL cells were isolated from the peripheral blood of untreated patients. The peripheral blood usually contained 4-9 × 10 10 leukocytes/l. Cell surface phenotyping revealed a staining pattern typical for B-CLL:
22 CD5, CD19, CD23, CD40, HLA class II positive with low expression of a light chain restricted surface IgM. All cells were CD10-negative.
Normal B lymphocytes were isolated from spleens of healthy patients. For B cell preparation spleen cells or peripheral blood of B-CLL patients were centrifuged through a FicollHypaque gradient at 900 g at 20°C. Macrophages were removed from lymphoid cells by adherence on plastic dishes. B lymphocytes were obtained after E-rosetting using AETtreated sheep erythrocytes as described. 23 B-CLL cells were usually enriched to 99% CD19-positive cells as shown by FACS analysis. Normal B cell preparations contained 94-97% CD19-positive cells. Isolated cells were further incubated in RPMI 1640 (Gibco) with 5 mm l-glutamine, 100 U/ml penicillin G, 100 ng/ml streptomycin (Seromed, Berlin, Germany) and 10% fetal calf serum (FCS; Gibco) at 37°C for the times indicated in the legends. Spleen cells were frozen before isolation of B lymphocytes in liquid nitrogen to allow the use of identical batches of B cells in control experiments.
Reagents
IL-2 and IL-4 were kindly provided by Prof Dr W Sebald (Theodor-Boveri-Institut, Wü rzburg, Germany). Monoclonal antibodies, PE or FITC coupled, were from Becton Dickinson (Heidelberg, Germany; Leu 12 (CD19), Leu 1 (CD 5), Leu 4 (CD3)), Dianova (Hamburg, Germany; IOT8 (CD23)) and Coulter (Krefeld, Germany; ␣-IgM, anti-k-chain, anti-l-chain). PKH26 (Sigma, Deisenhofen, Germany) was used according to the manufacturer's instructions. In detail, competitor cells (B-CLL cells or normal B lymphocytes) were incubated for 2 min with 1 mm PKH26 for optimal staining. PKH26 persisted in the cells for more than 48 h as shown by FACS analysis. Diffusion of PKH26 from marked cells into other co-cultivated cells, eg T cells, could not be observed by FACS analysis. PKH26 treatment of cells did not induce proliferation or CD23 expression on normal B cells or proliferation of T lymphocytes.
Cell culture techniques
Cell cultures were usually performed in 96-well flat-bottom microtiter plates (Falcon, Heidelberg, Germany) in 200 ml RPMI 1640 with 10% FCS and other supplements as indicated. For stimulation experiments with CD4 + T cell clones, wells were precoated with a monoclonal antibody against CD3 (purified ␣-CD3 antibodies were kindly provided by Prof Dr E Rieber, Dresden). For coating, 30 ml of a 10 g/ml solution of ␣-CD3mAb in PBS (phosphate-buffered saline) were incubated for 90 min at 37°C. Unbound antibodies were removed by washing three times with PBS. Cloned T cells were irradiated (30 Gy) Necessity of direct cell contact was tested using culture inserts with semipermeable membranes in 24-well plates (Falcon). T cells were pipetted into culture wells coated with ␣CD3 antibody. In similar experiments, CD40 ligand expressing mouse fibroblasts (L cells, 1.5 × 10 4 ) were used without stimulation with antibody. B-CLL cells, normal B lymphocytes or CD40-ligand expressing L cells (as indicated), were added to the culture wells directly, or they were placed in culture inserts, thus avoiding direct cellular contact between CD4
+ T cells and B-CLL cells. In every case the competitor cells (B-CLL cells or normal B lymphocytes) were marked with PKH26 (Sigma) before cultivation as described above.
FACS analysis
Three-color fluorescence staining (CD23-FITC (fluorescence 1), PKH26 (fluorescence 2) and CD4 quantum red (fluorescence 3)) allowed analysis of CD23 expression on normal B lymphocytes. The following three gates were combined: gate 1: definition of the lymphocyte population according to cell size and granularity (FSC vs SSC); gate 2: separation of T lymphocytes by gating on CD4 quantum red negative lymphocytes; gate 3: separation of competitor cells from normal B lymphocytes by gating on PKH26 negative lymphocytes.
Finally, expression of CD23 was determined on the remaining indicator B cells, defined as lymphocytes, negative for CD4 and PKH26.
Results
Induction of CD23 on splenic B lymphocytes depends upon direct cell contact
To investigate T cell/B cell interaction in vitro we cultured splenic B lymphocytes together with anti-CD3 activated CD4-positive T cell clones. B cell activation was analyzed by measuring inducible expression of the CD23 antigen on primary B cells. 24, 25 CD23 expression on B lymphocytes was determined by FACS analysis using double staining of B cells with CD19-PE and CD23-FITC monoclonal antibodies. In Figure 1 , B cell activation is shown by induction of the early activation antigen CD23. Under these conditions B cell activation depends upon direct cell contact as separation of T and B lymphocytes by semipermeable membranes in transwell experiments abolished the effect. Furthermore, IL-4, a main stimulator of CD23, could not replace direct T cell contact even when added in optimal doses ( Figure 1, exp 2) .
T cell-dependent activation of B lymphocytes is reduced by competition with B-CLL and normal B lymphocytes
B-CLL patients suffer from diverse defects of the immune system. One of the most important is the failure to produce anti- The analysis of 14 different B-CLL cases showed a varying degree of inhibition. Figure 2 illustrates the typical result of four B-CLL cases which ranged from a strong inhibition (CLL-3) to no measurable inhibition as in CLL-2. Six out of 14 B-CLL cases clearly inhibited parallel ongoing B cell activation. Table 1 illustrates the required amount of B cell competitor cells resulting in 25% or 50% inhibition of regular B lymphocyte activation. In eight out of 14 cases no inhibition could be observed up to the number of 1 × 10 6 'competitor cells'. The inhibitory capacity of each CLL case was highly reproducible. This is illustrated by Figures 2, 3 and 4 where CLL-2 and CLL-3 showed the same inhibition profile even in different B cell activation systems. Two additional points can be made regarding the experiments. First, the observed inhibition by B-CLL cells is not CLL-specific, since normal B cells are at least as potent in vitro (Figure 2) . Second, the observed inhibition is not simply due to cell crowding since B-CLL cells like CLL-2, -5, -6, -7, -9, -10, -11 and -13 fail to inhibit the response even when added in a 25-fold excess. Therefore the underly- 
Table 1
Inhibition of T cell-mediated B cell activation by different B-CLL cases
Competitor cell
Cell number Cell number required required for 25% for 50% inhibition inhibition ing mechanism directly seems to influence the transmission of T cell help.
CD40 ligand-mediated induction of CD23 on normal B cells can be inhibited by B-CLL cells
The CD40/CD40 ligand system is the central signal transducing complex in cell contact-mediated T cell help. We therefore considered it likely that interference with the CD40/CD40 ligand system was a reason for B-CLL-mediated inhibition of 
B-CLL can interact with CD40 ligand-transfected cells
The experiments using CD40 ligand-transfected L cells indicated that either direct modulation of the CD40L signal by B cells or B-CLL cells is responsible for the inhibition of parallel B cell activation. Since distinct B-CLL cases (ie CLL-2) repeatedly failed to show this inhibition, we asked whether these B-CLL cases simply were unable to interact with CD40L transfected fibroblasts. All CLL cases showed similar levels of CD40 expression as judged by FACS analysis irrespective of their ability to inhibit normal B cell activation. To address this question further, we analyzed the inducible CD23 expression on the competitor cells themselves stimulated by CD40 ligand transfected L cells. As shown in Figure 5 , CD40 ligand transfected L cells induced some CD23 expression on normal B cells and B-CLL cells. IL-4 alone was a good inducer of CD23 on normal B cells, whereas IL-4 mediated CD23 expression on B-CLL was usually quite modest. 11, 26 However, costimulation with CD40 ligand and IL-4 resulted in a strong activation of CD23 expression on normal B lymphocytes and B-CLL ( Figure 5 ). These experiments show that B-CLL cells, like normal B cells, are able to receive a stimulating signal by CD40L transfected fibroblasts. In particular, also cells from CLL-2 which fail to inhibit the CD40L signal (Figures 2 and 3) were fully able to receive a CD40L mediated stimulatory signal. Therefore the potency of inhibiting CD40L cannot be explained by the inability of certain B-CLL cases to interact with CD40L.
Discussion
Chronic lymphocytic leukemias are predominantly B cell neoplasms which are charcterized by the accumulation of slowly dividing monoclonal CD5-positive B cells. 1 The analysis of cell surface markers and transcription factors favors the assumption that B-CLL cells are representatives of activated B cells. 27, 28 These observations explain only in part the lifethreatening consequences of the disease such as high frequencies of hypogammaglobulinemia (60% of the patients), leading to bacterial infections, or autoimmunity directed against blood cell components (7.7 to 35% of the patients). The autoantibodies are in most cases produced by apparently normal B lymphocytes, 1, 6 ,29 indicating disturbance of the immune system in CLL patients. The events leading to the described phenomena are as yet unclear.
Normal B lymphocytes require help from activated T cells for antigen-specific activation and differentiation. This is mediated by cytokines such as IL-2, -4 and -5 and signals involving direct cell contact. 30 The most important cell contact mediated helper signal for B cells seems to be received via CD40 from CD40 ligand expressing activated T lymphocytes. 14, 19, 31 The signal directly activates resting B cells ( Figure 5 ) and enhances the responsiveness to other signals such as cytokines. 32 It is known that blocking the CD40/CD40 ligand interaction in vitro by monoclonal antibodies results in impaired B cell responses 20 and CD40 ligand-deficient individuals fail to undergo isotype switching and germinal center formation (hyper-IgM syndrome). 33 B-CLL cells express similar cell surface receptors and signal transducing molecules as do normal B-lymphocytes. 34 These surface receptors display a regular function and B-CLL cells respond to external signals such as lymphokines or direct cell contact-mediated T cell help in a way similar to normal B lymphocytes (Figures 1 and  5) . 34 Thus, it seems plausible that B-CLL cells and cells of the normal immune system communicate with each other in vivo leading to the observed immune dysregulation in B-CLL patients. Therefore we decided to investigate, whether B cell/T cell interaction in B-CLL is disturbed. Since B-CLL leukemic lymphocytes are found in excess in most compartments of the immune system, we addressed the question whether B-CLL cells are able to inhibit a T cell contact dependent in vitro model of B cell activation by competing for the cell contactmediated helper signals.
Normal B lymphocytes are activated by anti-CD3 stimulated CD4-positive T cell clones to express the activation molecule CD23. 24, 25 This activation depends on direct cell contact and can only partially be substituted for by cytokines such as IL-4 ( Figure 1 ). The addition of normal B lymphocytes or increasing numbers of certain B-CLL cells, resulted in a dosedependent inhibition of T cell contact-mediated B cell stimulation ( Figure 2) .
In order to break down the multiple possibilities of B cell/T cell interaction, 35 we assessed the role of the CD40/CD40 ligand system as target for the suppressed T cell-dependent B cell activation. Using CD40 ligand-transfected fibroblasts as substitute for activated T cell clones we show that the same B-CLL cells which inhibited the activation of normal B cells by a CD4-positive T cell clone also prevented their activation by CD40 ligand-transfected fibroblasts. This indicates that B-CLL directly interfere with the CD40 ligand-mediated helper signal. This inhibition also required direct cell contact between the inhibitory B-CLL cells and the indicator system of normal B lymphocytes and CD40 ligand expressing fibroblasts. Separating the inhibitory cells by semipermeable membranes shows unimpeded B cell stimulation, suggesting that the observed inhibition is mediated by blocking cell contactmediated signals, and not because of soluble factors secreted by the B-CLL cells added to the system (Figure 4) .
Lymphocytes from B-CLL patients showed considerable heterogeneity in their ability to suppress normal B cell activation. Some even completely failed to block cell contact-mediated B cell stimulation, even when high numbers of cells were added (Figures 2 and 3 , Table 1 ). Eight out of 14 CLL cases showed no inhibition, even when used in 25-fold excess ( Table 1) . The variability of different B-CLL cases to inhibit CD40L-mediated B cell activation is highly reproducible even when different sources of T cell help were used (CD4 positive T cells vs CD40L transfected fibroblasts). This is illustrated in Figures 2  and 3 where CLL-3 effectively inhibits normal B cell activation whereas CLL-2 repeatedly fails to do so. Since eight out of 14 B-CLL cases did not inhibit normal B cell activation, this strongly argues against a 'space problem' by merely reducing the probability of specific interactions between the normal 'indicator' B cells and the CD40L transfected fibroblasts (Figure 3 ) or CD4-positive T cell clones ( Figure 2 , Table 1 ).
So far the difference between inhibitory and not inhibitory B-CLL cases is not clear. The analysis of conventional B-CLL associated cell surface antigens like CD19, CD5, CD23 and particularly CD40 showed no quantitative differences as judged by FACS analysis. Furthermore all tested B-CLL responded to signals by CD40L transfected fibroblasts ( Figure 5 ). Thus the failure of B-CLL-2 to inhibit parallel B cell activation is not caused by the inability of these cells to interact with CD40L ( Figure 5 ). We can only speculate that in addition to CD40 other surface molecules, eg adhesion molecules, are required for effective competition for T cell help.
Antigen-derived B cell differentiation takes place in germinal centers of lymph nodes. B lymphocytes get activated in T cell-rich zones in association with interdigitating cells and T cell help with the CD40L-mediating signal playing a central role. 14, 36, 37 Disruption of the follicular microenvironment by B-CLL could disturb the tightly regulated cellular interactions which normally lead to the development of mature antibodysecreting plasma cells or memory cells. Therefore it can be envisaged that inhibition of the CD40 ligand transmitted helper signal by B-CLL cells, as demonstrated in this paper, may be one important mechanism for the observed immune suppression in B-CLL patients.
It is important to point out that inhibition of cell contactmediated T cell help is not specific to B-CLL cells since nor-mal B cells inhibit at least as well in vitro (Figure 2 ). However it has to be taken into account that in vivo the immunologic organs are highly compartmentalised and normal B cells do not regularly enter the regions where a coordinated T celldependent B cell activation takes place. In contrast, in B-CLL we have high B cell numbers which do not observe the regulated structures of lymph nodes. Under these circumstances it is conceivable that inhibition of CD40L signals becomes relevant and leads to the observed immune suppression. Thus cell number and homing pattern, rather than a specific cellular signal, determine the ability of B-CLL cells to suppress normal immune responses.
Recently it has been reported that B-CLL cells physically downmodulate CD40L expression on helper T cells. 38, 39 In these in vitro experiments excess numbers of B-CLL cells were necessary to downmodulate CD40L expression on T cells. We can reproduce these results using B-CLL or normal B cells. Thus, our results extend these studies by demonstrating a functional effect of the observed physical downmodulation of CD40L.
It seems likely that multiple causes lead to the immune dysregulation in B-CLL cells in vivo. It has been suggested that B-CLL cells are able to modulate T lymphocyte activation. Cocultivation of leukemic B cells with T lymphocytes profoundly influenced the cytokine profile of the non-malignant T cell population. Furthermore the secretion of cytokines by B-CLL cells themselves could also influence parallel specific immune responses. 40, 41 Nevertheless, the inhibition of T cell/B cell interaction by B-CLL described here, seems not to involve cytokine secretion (Figure 4) .
Hence, there are multiple mechanisms by which B-CLL cells can downregulate specific immune responses in vivo. Competitive inhibition or downmodulation of CD40 ligandmediated helper signals, as described in this paper, seems to be one plausible mechanism underlying the impairment of B cell function during disease progression in patients suffering from B-CLL.
